Since it has been recently reported that LILRB4 is an immune therapeutic target for M5 AML [28, 29], the working flow and outcome will benefit further experimental and clinical validation of the other 3 novel risk genes (LRRC25, NCF2 and RAB31), i.e. to access if they also function as therapeutic targets for monocytic AML as LILRB4. Here, LRRC25 is linked to acute myeloid leukemia.